While TP53 mutations are known to be early events, genomic analysis of clinical samples of BE and gastric intestinal metaplasia have demonstrated that the frequency of TP53 mutations is actually low (~2%) [18]. This evidence concerns the gene TP53 and Barrett esophagus.